DEFINE-FLOW: Combined Pressure and Flow Measurements to Guide Treatment of Coronary Stenoses

Sponsor
The University of Texas Health Science Center, Houston (Other)
Overall Status
Completed
CT.gov ID
NCT02328820
Collaborator
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (Other), Volcano Corporation (Industry)
455
12
1
78
37.9
0.5

Study Details

Study Description

Brief Summary

This study evaluates the prognostic value and therapeutic potential of combined pressure and flow measurements when evaluating a coronary artery stenosis. Lesions with intact coronary flow reserve (CFR) despite a reduced fractional flow reserve (FFR) will receive optimal medical therapy. Only lesions with a simultaneous reduction in both CFR and FFR will be treated with percutaneous coronary intervention (PCI).

Condition or Disease Intervention/Treatment Phase
  • Other: Percutaneous coronary intervention (PCI)
  • Other: Optimal medical therapy (OMT)
N/A

Detailed Description

Pressure and flow represent the two physiologic variables that can be measured directly inside a coronary artery. Already pressure measurements have proven their clinical value in the form of fractional flow reserve (FFR). However, myocardial function can remain intact with sufficient flow, even at a low perfusion pressure. Therefore, combined pressure and flow measurements provide a more complete description of physiologic stenosis severity as a guide to medical treatment versus revascularization. Based on existing work relating the most common flow measurement, coronary flow reserve (CFR), to FFR and linking both variables with subsequent prognosis, we hypothesize that lesions with an intact CFR>=2.0 can be reasonably treated with medical therapy despite a reduced FFR<=0.8.

Study Design

Study Type:
Interventional
Actual Enrollment :
455 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
DEFINE-FLOW (Distal Evaluation of Functional Performance With Intravascular Sensors to Assess the Narrowing Effect - Combined Pressure and Doppler FLOW Velocity Measurements)
Actual Study Start Date :
Oct 1, 2014
Actual Primary Completion Date :
Nov 1, 2019
Actual Study Completion Date :
Apr 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Other: All patients

All lesions undergo simultaneous assessment with a combined pressure and flow sensor

Other: Percutaneous coronary intervention (PCI)
For lesions with both FFR<=0.8 and CFR<2.0

Other: Optimal medical therapy (OMT)
For lesions with FFR>0.8 or CFR>=2.0 or both

Outcome Measures

Primary Outcome Measures

  1. Major adverse cardiac events [24 months]

    All-cause death, non-fatal myocardial infarction, urgent and elective revascularization

Secondary Outcome Measures

  1. Angina (Canadian Cardiovascular Society (CCS) anginal class (or freedom from angina) [24 months]

    Canadian Cardiovascular Society (CCS) anginal class (or freedom from angina)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age ≥ 18 years.

  • Eligible for PCI based on local practice standards during the current procedure (PCI cannot be staged).

  • At least one epicardial stenosis of ≥50% diameter (by visual or quantitative assessment) and meeting the following criteria as determined by the operator based on either a prior or the current diagnostic angiogram:

  • <100% diameter (not a chronic, total occlusion);

  • in a native coronary artery (including side branches but excludes bypass grafts);

  • of ≥2.5mm reference diameter (near the level of the stenosis);

  • and supplies sufficiently viable myocardium (exclude regions of known, prior, transmural myocardial infarction).

  • Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:
  • Anatomic exclusions:

  • Prior CABG.

  • Preferred treatment strategy for revascularization would be CABG based on local practice standards.

  • Left main coronary artery disease requiring revascularization.

  • Extremely tortuous or calcified coronary arteries precluding intracoronary physiologic measurements. Operators may also exclude subtotal or similar high-grade lesions, which in their judgment may be threatened by ComboWire placement.

  • Known severe LV hypertrophy (septal wall thickness at echocardiography of >13 mm).

  • Clinical exclusions:

  • Inability to receive intravenous adenosine (for example, severe reactive airway disease, marked hypotension, or high-grade AV block without pacemaker).

  • Recent (within 3 weeks prior to cardiac catheterization) ST-segment elevation myocardial infarction (STEMI) in any arterial distribution (not specifically target lesion).

  • Culprit lesions (based on clinical judgment of the operator) for either STEMI or non-STEMI cannot be included.

  • Severe cardiomyopathy (LV ejection fraction <30%).

  • Planned need for cardiac surgery (for example, valve surgery, treatment of aortic aneurysm, or septal myomectomy).

  • General exclusions:

  • A life expectancy of less than 2 years.

  • Inability to sign an informed consent, due to any mental condition that renders the subject unable to understand the nature, scope, and possible consequences of the trial or due to mental retardation or language barrier.

  • Potential for non-compliance towards the requirements for follow-up visits.

  • Participation or planned participation in another cardiovascular clinical trial before completing the 24 month follow-up.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Aarhus University Hospital Aarhus Denmark
2 Catholic University of the Sacred Heart Rome Italy
3 Gifu Heart Center Gifu Japan
4 Toda Central General Hospital Toda Japan
5 Tokyo Medical University Tokyo Japan
6 Tsuchiura Kyodo Tsuchiura Japan
7 Amsterdam UMC - location AMC Amsterdam Netherlands
8 Amsterdam UMC - location VUmc Amsterdam Netherlands
9 Tergooi Hospital Blaricum Netherlands
10 Amphia Hospital Breda Netherlands
11 Hospital Clinico San Carlos Madrid Spain
12 Royal Free Hospital London United Kingdom

Sponsors and Collaborators

  • The University of Texas Health Science Center, Houston
  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  • Volcano Corporation

Investigators

  • Principal Investigator: Nils Johnson, MD, University of Texas Medical School at Houston
  • Study Director: Jan J Piek, MD, PhD, Academic Medical Center (AMC), Amsterdam

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Nils Johnson, Associate Professor of Medicine, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier:
NCT02328820
Other Study ID Numbers:
  • HSC-MS-14-0442
  • NL48375.018.14
First Posted:
Dec 31, 2014
Last Update Posted:
Apr 6, 2021
Last Verified:
Apr 1, 2021
Keywords provided by Nils Johnson, Associate Professor of Medicine, The University of Texas Health Science Center, Houston
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 6, 2021